Buy back InnoCare Pharma and increase holdings in Allist, European-China Fund's Gran: The innovative drug industry chain is expected to continue driving industry growth
On August 30th, the three public funds managed by Ge Lan disclosed their semi-annual reports for 2025, revealing their hidden heavy holdings. Specifically, both the China Europe Medical Health and China Europe Medical Innovation funds significantly increased their holdings in Zai Lab Limited - U, while also newly investing in InnoCare Pharma - U and Allist. Additionally, Angli Kang, Shuyou Shen, and Di Zhe Pharmaceutical - U made their first appearance in the holdings of the two medical-themed funds. China Europe Mingrui New Starting Point purchased multiple bank stocks, including Bank of Ningbo, Agricultural Bank of China, Qingdao Bank, and China Construction Bank
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments